Discover how the three largest pharmacy benefit managers are rejecting biosimilars from their formularies, except for their own private-label drugs.
Abby Jones’ first stop of the day delivering medication was the home of 90-year-old Sarah Campbell Kier. “Come in!” yelled ...
FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback